ESC 365 - Heart Failure: What are the practical consequences of current and ongoing SGLT2i outcome trials?

ESC Premium Access

Heart Failure: What are the practical consequences of current and ongoing SGLT2i outcome trials?

Session: Expanding opportunities for SGLT2i in clinical cardiology

Topic: Clinical

Speaker: Professor F. Zannad (Vandoeuvre-Les-Nancy, FR)

Organised by PACE-CME, supported with an educational grant provided by Boehringer-Ingelheim/Lilly

Event: ESC Congress 2019

Congress Presentation

Add to my library

About the speaker

Professor Faiez Zannad

University of Lorraine, Vandoeuvre-Les-Nancy (France)

103 presentations

4 followers

4 more presentations in this session

Introduction

Speaker: Professor T. Luescher (London, GB)

The cardioprotective mechanisms of SGLT2 inhibitors: What do cardiologists need to know?

Speaker: Professor N. Marx (Aachen, DE)

Heart & Kidney interactions: What are the challenges for prevention and protection?

Speaker: Professor C. Wanner (Wuerzburg, DE)

Panel discussion

Speaker: Professor T. Luescher (London, GB)

Access the full session

Expanding opportunities for SGLT2i in clinical cardiology

Speakers: Professor F. Zannad, Professor T. Luescher, Professor N. Marx, Professor C. Wanner, Professor T. Luescher

About the event

ESC Congress 2019

31 August - 4 September 2019

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources